OncoZenge AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCOZ.ST research report →
Companywww.oncozenge.se
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden.
- CEO
- Stian Kildal
- IPO
- 2021
- Employees
- 1
- HQ
- Bromma, SE
Price Chart
Valuation
- Market Cap
- $99.46M
- P/E
- -5.62
- P/S
- 35.14
- P/B
- -152.54
- EV/EBITDA
- -6.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -557.92%
- Net Margin
- -563.25%
- ROE
- -202.18%
- ROIC
- -228.40%
Growth & Income
- Revenue
- $2.66M · 266300.00%
- Net Income
- $-15,940,000 · -83.47%
- EPS
- $-1.31 · -77.03%
- Op Income
- $-15,870,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $10.28
- 52W Low
- $4.51
- 50D MA
- $6.01
- 200D MA
- $6.00
- Beta
- 1.33
- Avg Volume
- 19.78K
Get TickerSpark's AI analysis on ONCOZ.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ONCOZ.ST Coverage
We haven't published any research on ONCOZ.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ONCOZ.ST Report →